The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis


Creative Commons License

Warrender-Sparkes M., Spelman T., Izquierdo G., Trojano M., Lugaresi A., Grand'Maison F., ...More

MULTIPLE SCLEROSIS JOURNAL, vol.22, no.4, pp.520-532, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 4
  • Publication Date: 2016
  • Doi Number: 10.1177/1352458515594041
  • Title of Journal : MULTIPLE SCLEROSIS JOURNAL
  • Page Numbers: pp.520-532
  • Keywords: Multiple sclerosis, disease-modifying therapy, fingolimod, medication persistence, MSBase, DISEASE-MODIFYING THERAPIES, INTERFERON-BETA THERAPY, TREATMENT PATTERNS, ADHERENCE, FINGOLIMOD, NATALIZUMAB

Abstract

Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS).